Ligand Pharmaceuticals financials
$310.36−1.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.7M | $51.7M | $59.7M | $115.5M | $47.6M | $45.3M | $42.8M | $51.8M | $41.5M | $31.0M | $28.1M | $32.9M |
| Gross profit | $52.4M | $40.4M | $56.7M | $111.7M | $36.5M | $32.2M | $40.0M | $49.4M | $38.6M | $28.1M | $26.5M | $29.4M |
| Gross margin | 82.2% | 78.0% | 95.0% | 96.7% | 76.6% | 71.1% | 93.4% | 95.3% | 93.0% | 90.7% | 94.2% | 89.4% |
| Operating income | $8.6M | $17.4M | $13.8M | $54.1M | $9.7M | -$36.7M | -$28.9M | $11.0M | $7.4M | $3.0M | -$3.4M | $957.0K |
| Net income | $48.5M | -$13.3M | $44.8M | $117.3M | $4.8M | -$42.5M | -$31.1M | -$7.2M | -$51.9M | $86.1M | $18.2M | -$10.3M |
| Net margin | 76.2% | −25.8% | 75.1% | 101.6% | 10.2% | −93.6% | −72.6% | −13.8% | −125.0% | 278.1% | 64.7% | −31.3% |
| Diluted EPS | $2.22 | $-0.67 | $2.09 | $5.68 | $0.24 | $-2.21 | $-1.67 | $-0.39 | $-2.88 | $4.75 | $1.01 | $-0.59 |
| EBITDA | $16.8M | $25.6M | $28.3M | $62.4M | $18.2M | -$27.9M | $10.3M | $19.9M | $16.2M | $11.8M | -$3.4M | $9.6M |
| Operating cash flow | $24.0M | $48.7M | $45.9M | $13.1M | $15.8M | -$25.4M | $28.5M | $36.5M | $13.3M | $18.7M | $8.1M | $7.6M |
| Free cash flow | $21.4M | $48.5M | $45.9M | $13.1M | $13.8M | -$25.7M | $27.8M | $35.9M | $12.9M | $18.6M | -$42.7M | $7.2M |
| Diluted shares | 21.8M | 19.9M | 21.4M | 20.6M | 19.9M | 19.2M | 18.6M | 18.4M | 18.0M | 18.1M | 17.9M | 17.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.01B | $115.1M | $174.9M | $139.4M | $67.7M | $48.0M |
| Short-term investments | $364.0M | $664.3M | $581.4M | $525.1M | $177.4M | $160.9M |
| Total debt | $1.13B | $446.9M | $446.2M | $445.5M | $24.0K | $24.0K |
| Total assets | $2.19B | $1.53B | $1.56B | $1.48B | $948.6M | $905.4M |
| Total liabilities | $1.22B | $534.8M | $543.4M | $526.6M | $120.1M | $109.9M |
| Shareholders' equity | $967.5M | $997.3M | $1.02B | $950.2M | $828.5M | $795.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology